DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells.

MLA

Bruyer, Angelique, et al. “DNMTi/HDACi Combined Epigenetic Targeted Treatment Induces Reprogramming of Myeloma Cells in the Direction of Normal Plasma Cells.” British Journal of Cancer, vol. 118, no. 8, Apr. 2018, pp. 1062–73. EBSCOhost, https://doi.org/10.1038/s41416-018-0025-x.

APA

Bruyer, A., Maes, K., Herviou, L., Kassambara, A., Seckinger, A., Cartron, G., Rème, T., Robert, N., Requirand, G., Boireau, S., Müller-Tidow, C., Veyrune, J.-L., Vincent, L., Bouhya, S., Goldschmidt, H., Vanderkerken, K., Hose, D., Klein, B., De Bruyne, E., & Moreaux, J. (2018). DNMTi/HDACi combined epigenetic targeted treatment induces reprogramming of myeloma cells in the direction of normal plasma cells. British Journal of Cancer, 118(8), 1062–1073. https://doi.org/10.1038/s41416-018-0025-x

Chicago

Bruyer, Angelique, Ken Maes, Laurie Herviou, Alboukadel Kassambara, Anja Seckinger, Guillaume Cartron, Thierry Rème, et al. 2018. “DNMTi/HDACi Combined Epigenetic Targeted Treatment Induces Reprogramming of Myeloma Cells in the Direction of Normal Plasma Cells.” British Journal of Cancer 118 (8): 1062–73. doi:10.1038/s41416-018-0025-x.